Abbott receives fda approval for tendyne™, first-of-its-kind device to replace the mitral valve without open-heart surgery

The tendyne system replaces mitral valves that are not functioning properly due to a buildup of calcium in the base of the valves, known as severe mitral annular calcification (mac) tendyne offers a new treatment option for patients who are not candidates for open-heart surgery or mitral repair this approval expands abbott's portfolio of minimally invasive structural heart therapies in the u.s. abbott park, ill., may 27, 2025 /prnewswire/ -- abbott (nyse: abt) today announced the u.s. food and drug administration (fda) has approved the company's tendyne™ transcatheter mitral valve replacement (tmvr) system to treat people with mitral valve disease.
ABT Ratings Summary
ABT Quant Ranking